Cannabis and Multiple Sclerosis: The Spasticity Evidence

Multiple sclerosis is the condition that took cannabinoids from anecdote to prescription in much of the world. Nabiximols, an oromucosal spray containing roughly equal THC and CBD, is approved in numerous countries for moderate to severe spasticity in MS that has not responded adequately to other treatment.

That makes this one of the few areas where the answer to "does cannabis help" is a qualified yes with a regulator behind it.

Spasticity: What the Evidence Says

Spasticity in MS is involuntary muscle stiffness and spasm from damage to the nerve pathways controlling muscle tone. It is painful, interferes with walking and sleep, and existing treatments such as baclofen and tizanidine have their own limits and side effects.

The 2017 National Academies review found substantial evidence that oral cannabinoids improve patient-reported multiple sclerosis spasticity symptoms. That is one of the highest ratings in the review.

Here is the wrinkle. The same review noted that evidence for improvement on objective clinician-measured spasticity was much weaker. Patients consistently report meaningful improvement. Instruments such as the Ashworth scale, which measures resistance to passive movement, frequently do not detect a matching change.

How To Read That Disagreement

Two interpretations are both plausible and probably both partly true.

The sceptical reading is that patients are reporting a general improvement in wellbeing, sleep or pain and attributing it to spasticity, with expectation effects contributing in a condition where blinding is difficult because THC is noticeable.

The other reading is that the Ashworth scale measures the wrong thing. It captures resistance to passive limb movement in a clinic. It does not capture spasm frequency, painful cramping at night, or how stiffness interferes with dressing and walking. A treatment could genuinely improve lived spasticity without moving that number.

For a patient, the patient-reported outcome is arguably the one that matters. For a regulator deciding what to approve, the gap is a legitimate reason for caution. Both positions are defensible, and the approvals reflect a judgement that the symptom benefit is real enough.

Beyond Spasticity

Pain. Central neuropathic pain is common in MS, and cannabinoids have moderate evidence in chronic and neuropathic pain generally. This is a reasonable secondary target.

Bladder dysfunction. Studied with mixed results. Some trials have reported reduced urinary urgency and incontinence episodes, and the evidence is not strong.

Sleep. Frequently improved, plausibly downstream of reduced spasm and pain rather than a direct effect.

Tremor. Not reliably improved. Patients sometimes expect this and the evidence does not support it.

Disease modification. Nabiximols treats symptoms. There is no established evidence that cannabinoids slow MS progression or reduce relapse rate, despite the immunosuppressive mechanism making it a reasonable research question. Disease-modifying therapies remain a separate and necessary part of care.

The Cognitive Trade-off

This concern is specific to MS rather than general. MS itself causes cognitive impairment in a substantial proportion of patients, affecting processing speed, memory and executive function.

THC also impairs those domains acutely. Adding a cognitively active drug to a disease that already affects cognition is a real trade-off, and studies have reported poorer cognitive performance in cannabis-using MS patients compared with non-users.

Whether that trade is worth making depends on how disabling the spasticity is and how much cognitive reserve someone has. It is exactly the kind of decision that needs a neurologist rather than a dispensary.

Practical Notes

Nabiximols is titrated slowly, typically building up sprays over days to find the minimum effective dose. That gradual approach is part of why it is tolerated.

Oromucosal delivery sits between inhaled and swallowed in onset, and avoids the airway.

Where nabiximols is unavailable, patients often use balanced THC and CBD products from regulated markets. The clinical evidence is for the standardised medicine, so expectations should be adjusted for products with less consistent dosing.

Do not stop disease-modifying therapy. Symptom relief is not disease control.

Bottom Line

MS spasticity is the clearest cannabinoid indication in neurology, with substantial evidence for patient-reported improvement and an approved medicine in nabiximols. Objective clinician measures often fail to confirm it, which is a real caveat rather than a debunking. Cognitive effects deserve genuine weight in MS specifically, and nothing here modifies the disease.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making any health-related decisions.